(Q31864356)

4 July 2017

title

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine (English)

1 reference

4 July 2017

0 references

G D Tollefson

1

1 reference

4 July 2017

M A Birkett

2

1 reference

4 July 2017

G M Kiesler

3

1 reference

4 July 2017

A J Wood

4

1 reference

4 July 2017

Lilly Resistant Schizophrenia Study Group

5

1 reference

4 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

4 July 2017

published in

Biological Psychiatry

1 reference

4 July 2017

volume

49

1 reference

4 July 2017

issue

1

1 reference

4 July 2017

page(s)

52-63

1 reference

A rating scale for drug-induced akathisia

4 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

The current status of the dopamine hypothesis of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

The natural history of schizophrenia in the long term

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

Clinical and statistical issues in therapeutic equivalence trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

Clozapine: progress in treating refractory schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

The positive and negative syndrome scale (PANSS) for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

The Mechanism of Action of Novel Antipsychotic Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

Clozapine's effect on negative symptoms in treatment-refractory schizophrenics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

Therapeutic equivalence investigations: statistical considerations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

Research Diagnoses for Tardive Dyskinesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901026-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(00)01026-X

1 reference

4 July 2017

1 reference